Shin Nippon Biomedical Laboratories (2395) · InitiativeAcquisition and cancellation of remaining rights
Raising Funds Through the Exercise of Stock Acquisition Rights
First written in FY2017-Q1. . Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Ongoing Increases in Capital and Capital Reserve Through the Exercise of Stock Acquisition RightsA theme 172 companies write about · 0 as a headwind · 167 as a tailwind
20 other companies' latest entry also says "Other".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 172 companies compared. The sentences above are computed from all 172.Full recordFilings, disclosures and news, newest first
- FY2017Acquisition and cancellation of remaining rightsAnnual report
「消却後に残存する新株予約権の数 0個」
FY2017中に18,564個を行使して1,856,400株を発行し、1,227,811千円を調達した。残存する41,436個については取得・消却され、残存数は0個となった。 - FY2017-Q1First statedAnnual report
「当社は、平成28年６月６日から平成28年６月24日までに、行使価額修正条項付第２回新株予約権の一部について権利行使がありました。」
期間中に1,856,400株が交付され、資本金617,618千円、資本剰余金617,618千円が増加し、資金調達額は1,227,811千円となった。